Therapy of human tumors in NOD/SCID mice with patient-derived reactivated memory T cells from bone marrow

[1]  G. Bastert,et al.  Enrichment of memory T cells and other profound immunological changes in the bone marrow from untreated breast cancer patients , 2001, International journal of cancer.

[2]  J. Schmitz,et al.  Simian immunodeficiency virus-specific cytotoxic T lymphocytes and cell-associated viral RNA levels in distinct lymphoid compartments of SIVmac-infected rhesus monkeys. , 2000, Blood.

[3]  D. Speiser,et al.  Naturally occurring human lymphocyte antigen-A2 restricted CD8+ T-cell response to the cancer testis antigen NY-ESO-1 in melanoma patients. , 2000, Cancer research.

[4]  Henrique Veiga-Fernandes,et al.  Response of naïve and memory CD8+ T cells to antigen stimulation in vivo , 2000, Nature Immunology.

[5]  H. Rammensee,et al.  The heat shock protein gp96 induces maturation of dendritic cells and down‐regulation of its receptor , 2000, European journal of immunology.

[6]  A. Gross,et al.  Regression of human metastatic renal cell carcinoma after vaccination with tumor cell–dendritic cell hybrids , 2000, Nature Medicine.

[7]  Nina Bhardwaj,et al.  Consequences of cell death: exposure to necrotic tumor cells , 2000 .

[8]  F. Sallusto,et al.  From synapses to immunological memory: the role of sustained T cell stimulation. , 2000, Current opinion in immunology.

[9]  N. Loder.  ‘Relevant’ teaching turns UK children back on to physics , 1999, Nature.

[10]  F. Sallusto,et al.  Two subsets of memory T lymphocytes with distinct homing potentials and effector functions , 1999, Nature.

[11]  E. Gilboa.  The makings of a tumor rejection antigen. , 1999, Immunity.

[12]  D. Lockhart,et al.  Functional Genomics , 1999, Springer Netherlands.

[13]  B. Stockinger,et al.  Following the development of a CD4 T cell response in vivo: from activation to memory formation. , 1999, Immunity.

[14]  R. Cote,et al.  Detection and clinical importance of micrometastatic disease. , 1999, Journal of the National Cancer Institute.

[15]  H. Rammensee,et al.  Identification of HLA-A2-restricted T-cell epitopes derived from the MUC1 tumor antigen for broadly applicable vaccine therapies. , 1999, Blood.

[16]  Mario Roederer,et al.  Characterization of circulating T cells specific for tumor-associated antigens in melanoma patients , 1999, Nature Medicine.

[17]  M. Cheever,et al.  Generation of immunity to the HER-2/neu oncogenic protein in patients with breast and ovarian cancer using a peptide-based vaccine. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[18]  Paul W Price,et al.  Characterization of CD4+ T cells in mouse bone marrow. I. Increased activated/memory phenotype and altered TCR Vβ repertoire , 1999, European journal of immunology.

[19]  S. Rosenberg,et al.  A new era for cancer immunotherapy based on the genes that encode cancer antigens. , 1999, Immunity.

[20]  H. Zerban,et al.  Graft-versus-leukemia reactivity involves cluster formation between superantigen-reactive donor T lymphocytes and host macrophages. , 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.

[21]  F. Gounari,et al.  EblacZ tumor dormancy in bone marrow and lymph nodes: active control of proliferating tumor cells by CD8+ immune T cells. , 1998, Cancer research.

[22]  J. Mulé,et al.  Murine dendritic cells pulsed with whole tumor lysates mediate potent antitumor immune responses in vitro and in vivo. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[23]  A. Cesano,et al.  Growth characteristics and metastatic properties of human breast cancer xenografts in immunodeficient mice. , 1998, The American journal of pathology.

[24]  Dirk Schadendorf,et al.  Vaccination of melanoma patients with peptide- or tumorlysate-pulsed dendritic cells , 1998, Nature Medicine.

[25]  M. Rep,et al.  Phenotypic and Functional Separation of Memory and Effector Human CD8+ T Cells , 1997, The Journal of experimental medicine.

[26]  A. McMichael,et al.  Rapid Effector Function in CD8+ Memory T Cells , 1997, The Journal of experimental medicine.

[27]  R. Ahmed,et al.  Bone marrow contains virus-specific cytotoxic T lymphocytes. , 1997, Blood.

[28]  C. Mackay,et al.  Human mucosal addressin cell adhesion molecule-1 is preferentially expressed in intestinal tract and associated lymphoid tissue. , 1997, The American journal of pathology.

[29]  F. Lemonnier,et al.  Differential requirements for survival and proliferation of CD8 naïve or memory T cells. , 1997, Science.

[30]  J. Sprent,et al.  Factors controlling the turnover of T memory cells , 1997, Immunological reviews.

[31]  M. Cooper,et al.  Memory B lymphocytes migrate to bone marrow in humans. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[32]  S. Braun,et al.  Re: Micrometastatic breast cancer cells in bone marrow at primary surgery: prognostic value in comparison with nodal status. , 1996, Journal of the National Cancer Institute.

[33]  M. Bevan,et al.  Selective activation of Fas/Fas ligand-mediated cytotoxicity by a self peptide , 1996, The Journal of experimental medicine.

[34]  R. Zinkernagel,et al.  Immunological Memory , 2006 .

[35]  A. Nagler,et al.  Allogeneic cell therapy with donor peripheral blood cells and recombinant human interleukin-2 to treat leukemia relapse after allogeneic bone marrow transplantation. , 1996, Blood.

[36]  C. Craddock,et al.  The VLA4/VCAM-1 adhesion pathway defines contrasting mechanisms of lodgement of transplanted murine hemopoietic progenitors between bone marrow and spleen. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[37]  G. Bastert,et al.  56. Long-term follow-up of breast cancer patients with micrometastatic tumour cells in bone marrow at primary surgery — prognostic impact in comparison to nodal status , 1995 .

[38]  R. Henderson,et al.  MUC‐1 Epithelial Tumor Mucin‐Based Immunity and Cancer Vaccines , 1995, Immunological reviews.

[39]  J. Wharton,et al.  Identification of an immunodominant peptide of HER-2/neu protooncogene recognized by ovarian tumor-specific cytotoxic T lymphocyte lines , 1995, The Journal of experimental medicine.

[40]  D. Greiner,et al.  Multiple defects in innate and adaptive immunologic function in NOD/LtSz-scid mice. , 1995, Journal of immunology.

[41]  R. Young,et al.  Naturally processed viral peptides recognized by cytotoxic T lymphocytes on cells chronically infected by human immunodeficiency virus type 1 , 1994, The Journal of experimental medicine.

[42]  S. Russell,et al.  Persistence of dormant tumor cells in the bone marrow of tumor cell-vaccinated mice correlates with long-term immunological protection. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[43]  B. Gückel,et al.  Tumour‐Specific CTL response requiring interactions of four different cell types and recognition of MHC class I and class II restricted tumour antigens , 1993, Immunology and cell biology.

[44]  E. Berg,et al.  α4β7 integrin mediates lymphocyte binding to the mucosal vascular addressin MAdCAM-1 , 1993, Cell.

[45]  S. Steinberg,et al.  Prospective randomized trial of high-dose interleukin-2 alone or in conjunction with lymphokine-activated killer cells for the treatment of patients with advanced cancer. , 1993, Journal of the National Cancer Institute.

[46]  M. Bevan,et al.  Selecting and maintaining a diverse T-cell repertoire , 1999, Nature.

[47]  M. Klein,et al.  Phenotypic and functional separation of memory and effector human CD 8 + T cells , 1997 .

[48]  R. Holle,et al.  Micrometastatic breast cancer cells in bone marrow at primary surgery: prognostic value in comparison with nodal status. , 1996, Journal of the National Cancer Institute.

[49]  C. Craddock,et al.  VLA4/VCAM‐1接着経路が骨髄とひ臓の間で移植したマウス造血幹細胞の対照的な定着機構を決定する , 1995 .